SecBot SecBot
6-K ·Filed Jun 12, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001171843-26-004073
Notable filing: 6-K
Actionable Insight • Neutral

This award is a reputational positive but does not alter Evaxion's clinical or financial outlook. Traders should monitor upcoming clinical data readouts and capital-raising activities for material catalysts. The stock's historical underperformance following prior neutral reports suggests limited near-term price reaction to this type of news.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.64
T+0 close · Jun 12, 2026 · via day close
Latest settled
−12.91%
T+60 · $3.17
Vs SPY
−16.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $3.64entry
  2. T+1 · 5mo ago −1.10%α −2.86% · $3.60
  3. T+5 · 5mo ago −16.21%α −16.88% · $3.05
  4. T+20 · 4mo ago −12.91%α −14.69% · $3.17
  5. T+60 · 2mo ago −12.91%α −16.18% · $3.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced it received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. This is a non-financial, non-regulatory recognition that provides external validation of the company's AI platform but does not change its clinical or financial trajectory. The filing is a routine press release with no material financial data or operational updates.

Key Facts

  • Evaxion received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform.
  • The award was presented at a ceremony at the Natural History Museum in London.
  • This is the second recognition from the Galien Prix Foundation in less than a year; the first was in December 2025 for Best Medical Technology / AI Advances in the Nordic and high-growth European and Middle Eastern countries.
  • The jury evaluated innovation in scientific development, clinical application, utility, insights in biomedical science, and tangible impact on human health.
  • No financial figures, clinical data, guidance, or material operational changes were disclosed in the filing.

Financial Impact

No financial impact disclosed; award is non-monetary and non-regulatory.

Risk Factors

  • Award does not accelerate clinical timelines or regulatory approvals.
  • No improvement in financial position or reduction in cash burn risk.
  • Market may view this as a non-material event given the company's pre-revenue status and need for additional capital.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-004073
Exhibit: exh_991.htm0001171843-26-004073
Document: 0001171843-26-004073-index-headers.html0001171843-26-004073
Document: 0001171843-26-004073-index.html0001171843-26-004073
Document: 0001171843-26-004073.txt0001171843-26-004073

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026